pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

epimab-biotherapeutics PRESS RELEASE ARCHIVE

Sep 19, 2023

EpimAb Biotherapeutics to Present Initial First-in-human Data of EMB-02 at the 2023 ESMO Conference

Jun 7, 2023

EpimAb Biotherapeutics Appoints Yonghong Zhu, M.D., Ph.D., as Chief Medical Officer

Jun 7, 2022

EpimAb Biotherapeutics Announces U.S. FDA Clearance of IND Application for Phase Ib/II Trial of EMB-01 in Combination with Tagrisso for Non-Small Cell Lung Cancer

Oct 11, 2021

EpimAb Biotherapeutics Strengthens Scientific Advisory Board with Addition of Andrew X. Zhu

Jul 6, 2021

EpimAb Biotherapeutics Provides Clinical Update for EMB-02 and EMB-06

May 26, 2021

EpimAb Biotherapeutics Appoints Jerry Su, Ph.D. as Chief Technology Officer

Mar 22, 2021

EpimAb Biotherapeutics Raises $120M in Series C Financing to Advance Bispecific Programs and Broaden Clinical Pipeline

Jan 25, 2021

Global Advanced Antibodies Report 2020 Featuring Affimed Therapeutics, AlphaMab Oncology, Chugai, EpimAb Biotherapeutics, Genmab, Macrogenics, Merus NV, Xencor and Zymeworks

Sep 15, 2020

EpimAb Biotherapeutics Announces FDA Clearance of its IND Application for EMB-02, a Bispecific Dual Checkpoint Inhibitor

Jul 24, 2020

EpimAb Biotherapeutics Strengthens Scientific Advisory Board with Addition of Professor Mark Smyth

Jun 22, 2020

EpimAb Biotherapeutics Presents Preclinical Data Characterizing EMB-01 at AACR Virtual Annual Meeting II

Apr 23, 2020

EpimAb Biotherapeutics and QIMR Berghofer Medical Research Institute Announce Research Collaboration and License Agreement on Novel Bispecific Target Combinations

Mar 24, 2020

EpimAb Biotherapeutics Appoints David Gu, Ph.D. as New Chief Financial Officer to Drive Corporate Development Plans

Jun 5, 2019

EpimAb Biotherapeutics Raises $74M in Series B Financing

Apr 24, 2019

EpimAb Biotherapeutics is Granted US Patent on Core Bispecific Antibody Technology

Jan 28, 2019

EpimAb Biotherapeutics Achieves Key Milestone with Lead Cancer Program EMB01

Sep 13, 2018

EpimAb Biotherapeutics Announces IND Filing for EMB01 in China and the US

Apr 23, 2018

EpimAb Biotherapeutics and Zhejiang Teruisi Biopharmaceutical Announce Development Collaboration on Epimab’s FIT012 Bispecific Antibody Program

Feb 26, 2018

EpimAb Biotherapeutics Appoints Industry Veteran Bin Peng as Chief Medical Officer

May 31, 2017

EpimAb Biotherapeutics Collaborates with WuXi Biologics to Advance Lead Bispecific Antibody Candidate towards Clinical Development

Apr 25, 2017

EpimAb Biotherapeutics Raises $25M in Series A Financing From International Consortium to Advance Pipeline of Novel Bispecific Antibodies

Oct 11, 2016

Kymab and EpimAb Biotherapeutics Announce Multi-Target, Bispecific Antibody Cross-Licensing Agreement

Jun 6, 2016

EpimAb Biotherapeutics and Innovent Biologics Announce Multi-Target Bispecific Antibody Collaboration

Google Analytics Alternative